Related Experiment Video
Updated: Aug 6, 2026
07:35
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
Published on: February 4, 2014
Management of clozapine-resistant schizophrenia
John Lally1,2,3, Siobhan Gee4,5,6,7, Caroline Hynes-Ryan8,9
1UCD Centre for Psychosis Research, School of Medicine, University College Dublin, Dublin, Ireland.
The Australian and New Zealand Journal of Psychiatry
|July 20, 2026
Summary
This study addresses managing schizophrenia cases resistant to clozapine treatment. It emphasizes systematic assessment to rule out pseudoresistance and optimize clozapine therapy before considering augmentation strategies.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Schizophrenia treatment guidelines highlight early clozapine initiation for treatment-resistant cases.
- Limited guidance exists for managing clozapine-resistant schizophrenia, leading to clinical practice variability.
Purpose of the Study:
- To provide evidence-informed recommendations for assessing and managing clozapine-resistant schizophrenia.
- To guide clinicians in optimizing clozapine therapy and considering augmentation strategies.
Main Methods:
- Systematic review of current evidence on clozapine resistance management.
- Emphasis on therapeutic drug monitoring and individualized clozapine dose optimization.
- Evaluation of augmentation strategies based on meta-analytic and real-world data.
Main Results:
- Early clozapine use is linked to better outcomes; delayed use correlates with poorer prognosis.
- Systematic assessment for pseudoresistance (non-adherence, interactions, metabolism, subtherapeutic levels) is crucial.
- Augmentation strategies show modest and inconsistent benefits; trials should be time-limited.
Conclusions:
- Optimizing clozapine through therapeutic drug monitoring and individualized adjustments is key.
- Augmentation should be considered only after adequate clozapine trials and should be systematically evaluated.
- Further research with standardized definitions and robust trials is needed for clozapine-resistant schizophrenia.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...